We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
76
Acadia Pharmaceuticals
ACAD
$4.55B
$5.76M 0.25%
160,147
– –
TEVA icon
77
Teva Pharmaceuticals
TEVA
$41.2B
$5.41M 0.24%
785,851
– –
DOC
78
DELISTED
PHYSICIANS REALTY TRUST
DOC
$5.39M 0.24%
303,908
– –
LH icon
79
Labcorp
LH
$25.9B
$5.28M 0.23%
36,578
– –
NKTR icon
80
Nektar Therapeutics
NKTR
$2.41B
$5.17M 0.23%
18,912
– –
ALGN icon
81
Align Technology
ALGN
$12.4B
$5.12M 0.22%
28,278
– –
PTCT icon
82
PTC Therapeutics
PTCT
$6.26B
$5.02M 0.22%
148,435
+8,827
+6% +$384K
RMD icon
83
ResMed
RMD
$30.3B
$5.01M 0.22%
37,110
-15,000
-29% -$1.97M
XNCR icon
84
Xencor
XNCR
$1.59B
$5M 0.22%
148,231
+75,849
+105% +$3.03M
PVLA
85
Palvella Therapeutics
PVLA
$2.15B
$4.94M 0.22%
18,116
– –
AGIO icon
86
Agios Pharmaceuticals
AGIO
$1.95B
$4.61M 0.2%
142,217
-3,125
-2% -$129K
GBT
87
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.51M 0.2%
92,957
+25,441
+38% +$1.33M
IQV icon
88
IQVIA
IQV
$39.1B
$4.46M 0.19%
29,857
+13,466
+82% +$2.1M
LGND icon
89
Ligand Pharmaceuticals
LGND
$5.94B
$4.38M 0.19%
70,620
– –
AMRN
90
Amarin Corp
AMRN
$298M
$4.38M 0.19%
14,428
-13,237
-48% -$4.62M
UTHR icon
91
United Therapeutics
UTHR
$26.2B
$4.31M 0.19%
54,094
– –
ACHC icon
92
Acadia Healthcare
ACHC
$2.62B
$4.23M 0.18%
136,200
-36,955
-21% -$1.13M
RARE icon
93
Ultragenyx Pharmaceutical
RARE
$2.56B
$4.17M 0.18%
97,480
+59,000
+153% +$3.21M
CRSP icon
94
CRISPR Therapeutics
CRSP
$4.77B
$4.15M 0.18%
101,336
-77,012
-43% -$3.68M
EPZM
95
DELISTED
Epizyme, Inc
EPZM
$4.12M 0.18%
399,604
– –
SNY icon
96
Sanofi
SNY
$103B
$3.98M 0.17%
85,941
– –
CHRS icon
97
Coherus Oncology
CHRS
$227M
$3.95M 0.17%
195,146
-96,273
-33% -$1.92M
MASI
98
DELISTED
Masimo
MASI
$3.93M 0.17%
26,436
-1,296
-5% -$197K
RGNX icon
99
Regenxbio
RGNX
$648M
$3.89M 0.17%
109,248
+96,447
+753% +$3.91M
ARGX icon
100
argenx
ARGX
$54.6B
$3.88M 0.17%
34,048
+5,667
+20% +$766K
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.